Only actual and fresh news

Recent media reports have covered research announced ahead of the American Academy of Neurology's (AAN) Annual Meeting in April which suggested that milk during pregnancy may lower a baby's risk of developing multiple sclerosis (MS) later in life. The theory from the researchers in Boston, announced in an AAN press release, was based on a survey of American mothers...

Drinking milk during pregnancy may help reduce your baby's chances of developing multiple sclerosis (MS) as an adult, according to a preliminary study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010...

Previous studies have shown multiple sclerosis (MS) patients are more often born in spring than in any other season, indicating that there is an environmental risk factor for the disease. A paper in the journal Neurology, reviewed for f1000 Medicine by Emmanuelle Waubant and Ellen Mowry, now suggests that this seasonal effect is mediated by the gene HLA-DRB1...

There is good news for women with multiple sclerosis (MS) who are pregnant or thinking about becoming pregnant. A new study shows that pregnant women with multiple sclerosis are only slightly more likely to have cesarean deliveries and babies with a poor prenatal growth rate than women who do not have MS...

For scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, what seemed like a disappointing result turned out to be an important discovery. Their findings, published online this week in the journal Proceedings of the National Academy of Sciences (PNAS), provide conclusive proof that, when a muscle is injured, white blood cells called macrophages play a crucial role in its regeneration.

A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss. The results of the trial in 21 people investigating the effects of pioglitazone (also known as Actos) were published last month in the Journal of Neuroimmunology.

A recently identified gene allows immune cells to start the self-destructive processes thought to underlie autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis, researchers at Washington University School of Medicine in St. Louis have found. Researchers showed that mice without the Batf gene lacked a type of inflammatory immune cell and were resistant to a procedure that normally induces an autoimmune condition similar to human MS.

Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array of compounds holds extraordinary potential for the treatment of multiple sclerosis, type 1 diabetes mellitus and numerous other autoimmune diseases. "This transaction is a significant milestone for Airmid. It places our peptidic Kv1.